Dietary Fat and Survival After Nonmetastatic Prostate Cancer

/in /by

A new cohort study published in JAMA Network provides some of the most detailed evidence to date on how the type of fat men eat after a prostate cancer diagnosis relates to long-term survival. The analysis, based on 4,884 participants in the Health Professionals Follow-Up Study followed for a median of 12.8 years, shows that […]

Read more

Phase 1 Trial: IL‑18–Armored STEAP1 CAR T Cells for Metastatic Castration‑Resistant Prostate Cancer

/in , , /by

IL‑18–armored STEAP1 CAR T cells represent a biologically rational, early‑clinical strategy that combines a well‑validated prostate‑cancer target with next‑generation cytokine armoring designed to overcome the hostile tumour microenvironment and antigen heterogeneity that have limited earlier immunotherapy efforts. STEAP1 (six‑transmembrane epithelial antigen of the prostate 1) was first identified in advanced prostate cancer and is now […]

Read more

De‑escalation therapy in metastatic prostate cancer: can some men safely stop ADT + ARPI after a deep response?

/in /by

For men with metastatic prostate cancer, the current standard is continuous androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) such as abiraterone, enzalutamide, apalutamide, or darolutamide. This approach improves survival but comes with substantial clinical and financial toxicity: fatigue, metabolic changes, sexual dysfunction, bone loss, cardiovascular risk, and long‑term treatment costs. The […]

Read more

Phase 3 Trial Tests a New B7-H3 Strategy in Advanced Prostate Cancer

/in , , /by

A new phase 3 clinical trial is preparing to evaluate risvutatug rezetecan, or Ris-Rez or GSK5764227, in men with metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that continues to progress despite androgen-deprivation treatment. The study, called EMBOLD Prostate-302, will compare this experimental therapy with best supportive or standard care, potentially including the […]

Read more

How Radium‑223 Plus Enzalutamide Accelerates ALP and PSA Responses in Bone‑Metastatic mCRPC

/in /by

An exploratory post hoc analysis of the international PEACE‑3 trial adds a compelling biomarker layer to the already positive story of combining radium‑223 with enzalutamide in men with bone‑metastatic, castration‑resistant prostate cancer. The parent study, a phase 3 randomised trial in asymptomatic or mildly symptomatic metastatic castration‑resistant prostate cancer (mCRPC) with bone metastases, had already […]

Read more

Phase 1 Trial: 177Lu-DTPA-SC16.56 in Neuroendocrine Prostate Cancer

/in , , /by

Neuroendocrine prostate cancer (NEPC) is a highly aggressive, treatment-resistant form of prostate cancer that emerges after androgen-deprivation therapies fail, leaving few effective options. Memorial Sloan Kettering Cancer Center is now running a Phase I trial testing a radiolabeled antibody called 177Lu-DTPA-SC16.56 in patients with progressive, chemotherapy-relapsed neuroendocrine prostate and lung cancers. DLL3 is the reason […]

Read more

UPDATE: Phase 3 Pivotal Trial for 177Lu-NYM032

/in , , /by

A PSMA-targeted radioligand built on a compound called NYM032 is heading into the pivotal phase 3 trial that will decide whether its early data hold up. The molecule can be labeled with gallium-68 for PET imaging or lutetium-177 for therapy, giving a matched diagnose-and-treat pair. In mouse tumor models, escalating the dose from 18.5 to […]

Read more

Beyond CRISPR? TIGRa: The Tiny Genetic Switch That Could Let the Body Heal Itself

/in , /by

Scientists at Stanford Medicine have built a new tool called TIGRa that can switch on helpful genes directly inside living cells. In a mouse study, it helped protect the eyes from a type of damage seen in glaucoma, and the discovery was published in the journal Cell Stem Cell. It could eventually lead to treatments […]

Read more